Quantum BioPharma Licensee Unbuzzd Wellness Announces Investor Webinar for $5 Million Offering

Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., will host an investor webinar on October 30, 2025, as part of its Regulation D 506(c) offering seeking to raise up to $5 million. The funding round is structured to avoid dilution to Quantum BioPharma shareholders, maintaining their equity position while providing capital for Unbuzzd's expansion. The webinar will feature key leadership including Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, former CEO of Celsius Holdings.

The event will focus on unbuzzd(TM), a scientifically proven beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms. This technology represents a significant advancement in the alcohol misuse treatment space, potentially offering consumers a practical solution for managing alcohol consumption effects. The leadership team will discuss strategic distribution plans and investment opportunities during the session, followed by a question and answer period for potential investors.

Quantum BioPharma retains substantial financial interest in Unbuzzd Wellness through its 20.11 percent ownership stake as of March 31, 2025, and royalty agreements that provide 7 percent of sales until payments reach $250 million, then decreasing to 3 percent in perpetuity. This arrangement ensures Quantum BioPharma benefits from Unbuzzd's commercial success while maintaining rights to develop similar products for pharmaceutical and medical applications. The full press release detailing this announcement is available at https://ibn.fm/yX7kt.

The investor webinar timing coincides with growing market interest in alcohol-related health solutions and represents an opportunity for investors to participate in a non-dilutive funding round. Unbuzzd's approach to alcohol metabolism acceleration could have broader implications for public health initiatives addressing alcohol misuse disorders. Quantum BioPharma's strategic positioning through its licensing agreement and equity stake demonstrates the company's commitment to advancing treatments across multiple therapeutic areas while generating revenue through successful commercial partnerships.